<DOC>
	<DOCNO>NCT01569711</DOCNO>
	<brief_summary>Depression common , recurrent disable disorder . Among patient chronic course disease , 20 30 % resistant antidepressant medication . Among patient , 50 % would benefit electroconvulsive therapy ( ECT ) . For patient , deep brain stimulation ( DBS ) nucleus accumbens consider .</brief_summary>
	<brief_title>Deep Brain Stimulation Nucleus Accumbens Chronic Resistant Major Depressive Disorder</brief_title>
	<detailed_description>Depression common ( 12-Month Prevalence general population : 6 % ) , recurrent disable disorder . Among patient chronic course disease , 20 30 % resistant antidepressant medication . Among patient respond favorably antidepressant medication , 50 % would benefit ECT . For patient , surgical intervention propose past . Many result support hypothesis dysfunction functional loop cortical subcortical structure underlie expression depressive disorder . Thus , therapeutic intervention focus loop , patient chronic depression resistant treatment , issue could improve prognosis patient . As part maximal resistance antidepressant drug , failure series bilateral ECT , surgical functional intervention use DBS nucleus accumbens consider . This open-label trial proposes assess feasibility , safety efficacy DBS nucleus accumbens patient chronic depression .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Patients 30 60 year old Meeting DSMIVTR major depressive disorder ( MDD ) , recurrent ( 296.3x ) diagnose use MINI scale Duration episode &gt; 2 year History recurrent MDD ( least one prior episode index ) , authenticate report ambulatory care hospitalization Meeting Thase Rush stage V resistance ( Thase Rush 1997 ) ( Annex 1 : mettre l'annexe ) Presenting simultaneously HDRS total score ( 17 item ) &gt; 21 , GAF &lt; 50 , score 4 CGI despite use follow strategy : monotherapy : 2 SSRIs , 1 ISRNA , 1 tricyclic ( measurement plasma ) maximum prescribed period 8 week association least one previous antidepressant , least six week one follow treatment : lithium , thyroid hormone , buspirone , pindolol . An intolerance one drug treatment related known side effect consider equivalent lack effect treatment irreversible MAOI : iproniazid ( Marsilid * ) combination 2 antipsychotic , least second generation antipsychotic ( olanzapine , risperidone , amisulpride , aripiprazole clozapine ) combination 2 antidepressant ECT : least 8 session maximal load crisis GET &gt; 25 sec bilaterally . If possible cognitive impairment : unilateral structure psychotherapy inspired cognitivebehavioral type structure psychotherapy period one year Understanding study Giving write , free inform consent Affiliated social security Serious unstable medical condition ( cardiovascular , respiratory , endocrine , metabolic , liver , renal , hematologic , infectious , neurological ... ) make impossible establishment study treatment Cognitive deterioration ( Mattis &lt; 130 ) Abnormal brain standard MRI contraindication MRI Axis 1 disorder MDD ( except generalize anxiety disorder , social phobia , panic disorder ) Addiction alcohol psychoactive substance exception nicotine suicide risk last month ( MINI 5.0.0 : section suicide risk DIGS : section intent , premeditation , lethality ) score &gt; 2 item 3 HDRS More two suicide attempt within two year prior inclusion MDD psychotic feature congruent incongruent mood history MDD psychotic feature Diagnostic criterion personality disorder accord DSMIVTR Cluster A B evaluate use SCID2 ( Maffei et al. , 1997 ) Involuntary commitment , guardianship trusteeship Women childbearing without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>chronic resistant major depressive disorder</keyword>
	<keyword>deep brain stimulation</keyword>
</DOC>